Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sutimlimab in Cold Agglutinin Disease
Alexander Röth, Wilma Barcellini, Shirley D’Sa, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 14, pp. 1323-1334
Open Access | Times Cited: 156

Showing 1-25 of 156 citing articles:

Antibodies to watch in 2022
Hélène Kaplon, Alicia M. Chenoweth, Silvia Crescioli, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 303
Autoimmune Hemolytic Anemias
Sigbjørn Berentsen, Wilma Barcellini
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1407-1419
Closed Access | Times Cited: 140
Tipping the balance: intricate roles of the complement system in disease and therapy
Richard B. Pouw, Daniel Ricklin
Seminars in Immunopathology (2021) Vol. 43, Iss. 6, pp. 757-771
Open Access | Times Cited: 115
A guide to complement biology, pathology and therapeutic opportunity
Dimitrios C. Mastellos, George Hajishengallis, John D. Lambris
Nature reviews. Immunology (2023) Vol. 24, Iss. 2, pp. 118-141
Closed Access | Times Cited: 104
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
Blood (2022) Vol. 140, Iss. 9, pp. 980-991
Open Access | Times Cited: 73
Complement in human disease: approved and up-and-coming therapeutics
Erin E. West, Trent M. Woodruff, Véronique Frémeaux‐Bacchi, et al.
The Lancet (2023) Vol. 403, Iss. 10424, pp. 392-405
Open Access | Times Cited: 60
IgM monoclonal gammopathies of clinical significance: diagnosis and management
Jahanzaib Khwaja, Shirley D’Sa, Monique C. Minnema, et al.
Haematologica (2022) Vol. 107, Iss. 9, pp. 2037-2050
Open Access | Times Cited: 48
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Tong‐Yuan Yang, Manuela Braun, Wibke Lembke, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 26, pp. 471-494
Open Access | Times Cited: 48
The role of complement in kidney disease
Vojtěch Petr, Joshua M. Thurman
Nature Reviews Nephrology (2023) Vol. 19, Iss. 12, pp. 771-787
Closed Access | Times Cited: 39
Therapeutic Antibodies in Medicine
Prerna Sharma, Rahul V. Joshi, Robert C. Pritchard, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6438-6438
Open Access | Times Cited: 29
The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?
Sigbjørn Berentsen, Bruno Fattizzo, Wilma Barcellini
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 25
Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy
Björn Laffer, Malte Lenders, Elvira Ehlers-Jeske, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
Marit Jalink, Chaja F. Jacobs, Jahanzaib Khwaja, et al.
Blood Advances (2024) Vol. 8, Iss. 11, pp. 2622-2634
Open Access | Times Cited: 10
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study
Xin Zhao, Jing Sun, Zhihua Zhang, et al.
The Lancet Haematology (2025)
Closed Access | Times Cited: 1
Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond
Eleni Gavriilaki, Régis Peffault de Latour, Antonio M. Risitano
Blood (2021) Vol. 139, Iss. 25, pp. 3571-3582
Open Access | Times Cited: 48
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome
Marit Jalink, Sigbjørn Berentsen, Jorge J. Castillo, et al.
Blood (2021) Vol. 138, Iss. 20, pp. 2002-2005
Open Access | Times Cited: 42
Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature
Bruno Fattizzo, Raffaella Pasquale, Valentina Bellani, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 42
Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
Catherine M. Broome, Alexander Röth, David J. Kuter, et al.
Blood Advances (2022) Vol. 7, Iss. 6, pp. 987-996
Open Access | Times Cited: 37
Autoimmune hemolytic anemia: causes and consequences
Bruno Fattizzo, Wilma Barcellini
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 7, pp. 731-745
Open Access | Times Cited: 35
The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration
Ying Chen, John Man Tak Chu, Raymond Chuen‐Chung Chang, et al.
Biomolecules (2022) Vol. 12, Iss. 2, pp. 337-337
Open Access | Times Cited: 34
Sutimlimab for Treatment of Cold Agglutinin Disease: Why, How And For Whom?
Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, et al.
Immunotherapy (2022) Vol. 14, Iss. 15, pp. 1191-1204
Open Access | Times Cited: 33
Molecular pharmacology in complement‐mediated hemolytic disorders
Marta Bortolotti, Wilma Barcellini, Bruno Fattizzo
European Journal Of Haematology (2023) Vol. 111, Iss. 3, pp. 326-336
Open Access | Times Cited: 18
Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics
Yazan Migdady, Yifan Pang, Shelley S. Kalsi, et al.
Blood Advances (2021) Vol. 6, Iss. 8, pp. 2707-2721
Open Access | Times Cited: 33
Complement biology for hematologists
Anna Duval, Véronique Frémeaux‐Bacchi
American Journal of Hematology (2023) Vol. 98, Iss. S4
Open Access | Times Cited: 16
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease
Alexander Röth, Wilma Barcellini, Shirley D’Sa, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1246-1253
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top